Twelve patients with sulfonylurea-treated non-insulin-dependent diabetes mellitus (SU-NIDDM), six with insulin-treated NIDDM (I-NIDDM) and eleven with insulin-dependent diabetes mellitus (IDDM) were subjected to strict control (SC) using an artificial pancreas (Biostator®) for 24 hours, and serum ketone body and lipid levels were examined comparatively between conventional therapy and 24-hour SC.
As a result, significant increases in total serum ketone body (TKB)(90±18 vs 211±52 μmol/
l, p<0.01) and free fatty acid (FFA)(410±86 vs 869±160 μEq/
l, p<0.05) and a significant decrease in serum triglyceride (TG)(116±9 vs 92±7 mg/d
l, p<0.05) with the strict control regime were noted for SU-NIDDM. These changes were not observed in I-NIDDM, although there was no difference between I-NIDDM and SU-NIDDM in plasma glucose, HbA
1c, FFA and TG levels before strict control. In IDDM, a significant decrease in TKB alone was observed. Addition of sulfonylurea during strict control in SU-NIDDM reduced elevated TKB levels significantly, while FFA remained unchanged. In light of these results it was supposed that the sequence of TKB change observed in SU-NIDDM was related mainly to sulfonylurea administration.
Moreover, additional administration of sulfonylurea in six patients with NIDDM on conventional insulin therapy decreased their TKB levels significantly (130±17 vs 78±8, p<0.05) in spite of unchanged plasma glucose and FFA.
These results suggest that sulfonylurea may inhibit hepatic ketogenesis in diabetic patients, a phenomenon previously shown in diabetic animals.
View full abstract